Long-term vemurafenib treatment drives inhibitor resistance through a spontaneous KRAS G12D mutation in a BRAF V600E papillary thyroid carcinoma model

The BRAF V600E mutation is commonly observed in papillary thyroid cancer (PTC) and predominantly activates the MAPK pathway. Presence of BRAF V600E predicts increasing risk of recurrence and higher mortality rate, and treatment options for such patients are limited. Vemurafenib, a BRAF V600E inhibit...

Descripción completa

Detalles Bibliográficos
Autores principales: Danysh, Brian P., Rieger, Erin Y., Sinha, Deepankar K., Evers, Caitlin V., Cote, Gilbert J., Cabanillas, Maria E., Hofmann, Marie-Claude
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5058727/
https://www.ncbi.nlm.nih.gov/pubmed/27127178
http://dx.doi.org/10.18632/oncotarget.9023

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5058727/
https://www.ncbi.nlm.nih.gov/pubmed/27127178
http://dx.doi.org/10.18632/oncotarget.9023

Ejemplares similares